Email me when Opaleye Management Inc. files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | 43 | $707M | +$80.8M | -$57.9M | +$22.9M | HROW, ETON, LQDA, RYTM, IMNM | 13F-HR | 11/14/2025, 04:05 PM |
| Q2 2025 | 41 | $494M | +$57.1M | -$40M | +$17.1M | HROW, ETON, IMNM, SNWV, LQDA | Restatement | 8/15/2025, 11:00 AM |
| Q1 2025 | 45 | $449M | +$101M | -$142M | -$41.6M | HROW, ETON, SNWV, LQDA, RYTM | 13F-HR | 5/15/2025, 04:10 PM |
| Q4 2024 | 39 | $571M | +$40.1M | -$63.7M | -$23.6M | HROW, TGTX, CDXS, ETON, OCUL | 13F-HR | 2/14/2025, 04:05 PM |
| Q3 2024 | 44 | $600M | +$72.9M | -$66.9M | +$6.02M | HROW, TGTX, OCUL, ARVN, CDXS | 13F-HR | 11/14/2024, 04:05 PM |
| Q2 2024 | 51 | $438M | +$72.2M | -$59.2M | +$13M | HROW, TGTX, OCUL, RYTM, KROS | 13F-HR | 8/14/2024, 04:05 PM |
| Q1 2024 | 51 | $455M | +$76.9M | -$77.5M | -$609K | OCUL, HROW, TGTX, KROS, RYTM | Restatement | 5/29/2024, 04:05 PM |
| Q4 2023 | 45 | $372M | +$63M | -$56.4M | +$6.61M | HROW, TGTX, SLRN, RYTM, OCUL | 13F-HR | 2/14/2024, 04:05 PM |
| Q3 2023 | 53 | $304M | +$47.9M | -$88.3M | -$40.4M | HROW, SLRN, OCUL, TGTX, RYTM | 13F-HR | 11/14/2023, 08:04 PM |
| Q2 2023 | 50 | $415M | +$135M | -$34.6M | +$100M | SLRN, HROW, OCUL, TELA, CRNX | 13F-HR | 8/14/2023, 06:11 PM |
| Q1 2023 | 41 | $334M | +$42.1M | -$6.65M | +$35.5M | HROW, OCUL, TELA, RYTM, CRNX | 13F-HR | 5/12/2023, 06:49 PM |
| Q4 2022 | 40 | $288M | +$59.8M | -$21.8M | +$38M | HROW, TELA, RYTM, OCUL, CRNX | 13F-HR | 2/10/2023, 03:05 PM |
| Q3 2022 | 42 | $242M | +$30.5M | -$14.3M | +$16.2M | HROW, OCUL, RYTM, TELA, CRNX | 13F-HR | 11/14/2022, 03:20 PM |
| Q2 2022 | 47 | $222M | +$35.6M | -$30.8M | +$4.78M | HROW, OCUL, CDXS, CRNX, CYTK | 13F-HR | 8/15/2022, 04:03 PM |
| Q1 2022 | 44 | $316M | +$33.3M | -$47.8M | -$14.5M | OCUL, CDXS, CMRX, HROW, CRNX | 13F-HR | 5/16/2022, 04:05 PM |
| Q4 2021 | 37 | $466M | +$50.2M | -$30.8M | +$19.4M | CDXS, OCUL, CMRX, CLDX, HROW | 13F-HR | 2/14/2022, 03:05 PM |
| Q3 2021 | 48 | $535M | +$61M | -$50M | +$11M | OCUL, CLDX, CDXS, CMRX, HROW | 13F-HR | 11/15/2021, 07:17 PM |
| Q2 2021 | 48 | $602M | +$45.2M | -$90.3M | -$45.1M | OCUL, CMRX, CLDX, BBIO, CDXS | 13F-HR | 8/16/2021, 05:13 PM |
| Q1 2021 | 57 | $671M | +$147M | -$168M | -$21.4M | OCUL, CMRX, TARA, BBIO, CDXS | 13F-HR | 5/17/2021, 07:03 PM |
| Q4 2020 | 57 | $748M | +$84.4M | -$20M | +$64.4M | OCUL, TARA, EIDX, ETON, CDXS | 13F-HR | 2/12/2021, 04:15 PM |
| Q3 2020 | 49 | $479M | +$114M | -$23.6M | +$90.5M | OCUL, TARA, ETON, CRDF, AFIB | 13F-HR | 11/16/2020, 03:30 PM |
| Q2 2020 | 47 | $487M | +$183M | -$21.2M | +$162M | TARA, OCUL, NLTX, CCXI, ETON | 13F-HR | 8/14/2020, 04:47 PM |
| Q1 2020 | 44 | $377M | +$103M | -$31.8M | +$71.6M | TARA, FTSV, OCUL, NLTX, CDXS | 13F-HR | 5/15/2020, 04:30 PM |
| Q4 2019 | 47 | $510M | +$106M | -$2.84M | +$104M | EPZM, CDXS, FTSV, STXS, TPTX | 13F-HR | 2/14/2020, 03:30 PM |
| Q3 2019 | 49 | $269M | +$67.5M | -$20.1M | +$47.4M | CDXS, STXS, EPZM, IMMY, EIDX | 13F-HR | 11/14/2019, 03:30 PM |
| Q2 2019 | 43 | $318M | +$63.5M | -$15.9M | +$47.6M | CDXS, IMMY, AXGN, EPZM, QURE | 13F-HR | 8/14/2019, 04:30 PM |
| Q1 2019 | 53 | $354M | +$127M | -$50.9M | +$76.2M | CDXS, AXGN, EPZM, CERC, AMRN | 13F-HR | 5/15/2019, 04:30 PM |
| Q4 2018 | 46 | $268M | +$47.4M | -$19.3M | +$28.2M | CDXS, AXGN, LOXO, AMRN, BPMC | 13F-HR | 2/14/2019, 04:00 PM |
| Q3 2018 | 46 | $393M | +$45M | -$41.6M | +$3.35M | AXGN, CDXS, LOXO, AMRN, BPMC | 13F-HR | 11/14/2018, 03:30 PM |
| Q2 2018 | 35 | $383M | +$94.3M | -$33.1M | +$61.2M | AXGN, LOXO, CDXS, FGEN, BPMC | 13F-HR | 8/14/2018, 04:31 PM |
| Q1 2018 | 37 | $329M | +$54.6M | -$23.7M | +$30.8M | AXGN, BPMC, LOXO, CDXS, FGEN | 13F-HR | 5/14/2018, 05:00 PM |
| Q4 2017 | 35 | $302M | +$53.2M | -$5.22M | +$48M | AXGN, BPMC, FGEN, LOXO, IMMU | 13F-HR | 2/9/2018, 03:30 PM |
| Q3 2017 | 32 | $281M | +$36.5M | -$12.3M | +$24.2M | BPMC, AXGN, FGEN, IMMU, LOXO | 13F-HR | 11/14/2017, 03:17 PM |
| Q2 2017 | 41 | $238M | +$36.2M | -$2.69M | +$33.5M | BPMC, AXGN, FGEN, LOXO, SBBP | 13F-HR | 8/14/2017, 04:34 PM |
| Q1 2017 | 43 | $198M | +$40.9M | -$8.45M | +$32.4M | BPMC, AXGN, FGEN, NVLNF, CMRX | 13F-HR | 5/15/2017, 06:15 AM |
| Q4 2016 | 39 | $168M | +$44.5M | -$10.3M | +$34.2M | BPMC, AXGN, ARIA, GNMX, FGEN | 13F-HR | 2/21/2017, 03:27 PM |
| Q3 2016 | 43 | $185M | +$33M | -$22.4M | +$10.5M | BPMC, AXGN, ARIA, MDGN, AGIO | 13F-HR | 11/14/2016, 11:30 AM |
| Q2 2016 | 49 | $144M | +$30.6M | -$8.99M | +$21.7M | AXGN, MDGN, ARIA, FGEN, BPMC | Restatement | 8/12/2016, 04:35 PM |
| Q1 2016 | 50 | $147M | +$32.7M | -$14M | +$18.7M | AXGN, ARIA, RARE, FGEN, MDGN | Restatement | 5/27/2016, 03:29 PM |
| Q4 2015 | 51 | $231M | +$45.5M | -$18.1M | +$27.4M | RARE, AXGN, FGEN, GERN, MDGN | 13F-HR | 2/12/2016, 11:57 AM |
| Q3 2015 | 47 | $199M | +$31.8M | -$24.1M | +$7.78M | CMRX, RARE, CEMP, AXGN, MDGN | 13F-HR | 11/13/2015, 09:44 AM |
| Q2 2015 | 43 | $243M | +$41.6M | -$20.9M | +$20.7M | CMRX, CEMP, RTRX, AMAG, ARIA | 13F-HR | 8/14/2015, 10:27 AM |
| Q1 2015 | 37 | $215M | +$50.1M | -$24.7M | +$25.4M | CMRX, CEMP, ARIA, RTRX, CLVSQ | 13F-HR | 5/15/2015, 11:41 AM |
| Q4 2014 | 36 | $198M | +$53.6M | -$4.72M | +$48.9M | CMRX, AGIO, CEMP, RTRX, ARIA | 13F-HR | 2/13/2015, 06:06 AM |
| Q3 2014 | 28 | $128M | +$25.7M | -$7.77M | +$18M | CMRX, PCYC, RTRX, ARIA, AGIO | 13F-HR | 11/14/2014, 09:27 AM |
| Q2 2014 | 27 | $116M | +$30.2M | -$3.59M | +$26.6M | CMRX, RTRX, ARIA, PCYC, GNMK | 13F-HR | 8/14/2014, 10:19 AM |
| Q1 2014 | 30 | $135M | +$63.5M | -$13.5M | +$50M | RTRX, ARIA, CMRX, PCYC, NSPR | 13F-HR | 5/15/2014, 10:48 AM |
| Q4 2013 | 21 | $122M | GENTY, GERN, PCYC, ARIA, P103PS | 13F-HR | 2/13/2014, 06:29 PM |